Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ATRA

Atara Biotherapeutics Inc

Dec 05 • 04:00PM ET

0.6313

Dollar change -0.0690
Percentage change -9.85	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.77	Insider Own	5.93%	Shs Outstand	95.93M	Perf Week	3.39%
Market Cap	64.34M	Forward P/E	-	EPS next Y	-1.16	Insider Trans	12.35%	Shs Float	95.88M	Perf Month	-51.06%
Income	-290.25M	PEG	-	EPS next Q	-0.49	Inst Own	98.03%	Short Float / Ratio	8.51% / 2.07	Perf Quarter	-59.79%
Sales	4.54M	P/S	14.17	EPS this Y	-11.24%	Inst Trans	-0.22%	Short Interest	8.16M	Perf Half Y	-61.51%
Book/sh	-0.50	P/B	-	EPS next Y	53.31%	ROA	-104.20%	Target Price	9.46	Perf Year	-86.74%
Cash/sh	1.01	P/C	0.63	EPS next 5Y	-	ROE	-425.97%	52W Range	0.20 - 5.64	Perf YTD	-80.75%
Dividend	-	P/FCF	-	EPS past 5Y	10.97%	ROI	-	52W High	-88.81%	Beta	0.70
Dividend %	-	Quick Ratio	1.42	Sales past 5Y	42.51%	Gross Margin	-390.18%	52W Low	217.88%	ATR	0.13
Employees	334	Current Ratio	1.50	Sales Q/Q	-52.05%	Oper. Margin	-6417.09%	RSI (14)	41.58	Volatility	15.86% 24.17%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	20.10%	Profit Margin	-6390.31%	Rel Volume	0.37	Prev Close	0.70
Shortable	Yes	LT Debt/Eq	-	Earnings	Nov 01 BMO	Payout	-	Avg Volume	3.94M	Price	0.63
Recom	2.71	SMA20	0.73%	SMA50	-43.33%	SMA200	-68.54%	Volume	1,456,351	Change	-9.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-09-23	Downgrade	Mizuho	Buy → Neutral	$31 → $1
Nov-09-23	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-09-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Downgrade	Citigroup	Neutral → Sell	$8 → $3
Jul-13-22	Downgrade	Stifel	Buy → Hold	$16 → $5
Jul-13-22	Downgrade	JP Morgan	Overweight → Neutral	$10
May-10-22	Downgrade	Citigroup	Buy → Neutral	$15 → $8
May-13-21	Upgrade	JP Morgan	Neutral → Overweight	$23 → $29
Dec-09-20	Downgrade	Citigroup	Buy → Neutral	$20 → $27
Dec-08-20	Reiterated	H.C. Wainwright	Buy	$28 → $31
Nov-10-20	Reiterated	H.C. Wainwright	Buy	$26 → $28
Jun-30-20	Initiated	Evercore ISI	Outperform
Jun-15-20	Initiated	H.C. Wainwright	Buy	$25
Apr-23-20	Upgrade	Citigroup	Neutral → Buy	$14
Nov-08-19	Downgrade	JP Morgan	Overweight → Neutral	$43 → $22
Sep-27-19	Downgrade	Goldman	Neutral → Sell	$14 → $9
Sep-16-19	Downgrade	Jefferies	Buy → Hold	$32 → $15
Jun-04-19	Upgrade	Citigroup	Sell → Neutral	$23 → $24
May-30-19	Initiated	ROTH Capital	Buy
May-23-19	Initiated	Stifel	Buy

Show Previous Ratings

Dec-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-29-23 06:05PM	Atara Biotherapeutics To Present Positive New Tab-cel Clinical Data During Oral Session at ESMO Immuno-Oncology Annual Congress 2023 (Business Wire) +13.36%
Nov-24-23 12:29PM	Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why (Zacks) +13.93%
Nov-22-23 04:01PM	Atara Biotherapeutics to Participate at the 6th Annual Evercore ISI HealthCONx Conference (Business Wire) +13.22%
09:14AM	Billionaire Seth Klarmans Biotech Stock Picks (Insider Monkey)
04:01PM	Loading…
Nov-10-23 04:01PM	Atara Biotherapeutics To Participate at the Stifel Healthcare Conference (Business Wire)
Nov-09-23 08:23AM	Why Is Atara Biotherapeutics (ATRA) Stock Down 50% Today? (InvestorPlace) -80.17%
06:40AM	Ataras cell therapy approach to MS falls short in study (BioPharma Dive)
Nov-08-23 05:35PM	Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis (Business Wire) -9.02%
Nov-05-23 12:50PM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-02-23 05:42AM	Atara Biotherapeutics Inc (ATRA) Announces Q3 2023 Financial Results and Expanded Global Partnership (GuruFocus.com) -5.56%
02:25AM	Q3 2023 Atara Biotherapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 08:35AM	Atara Biotherapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:30AM	Atara Biotherapeutics Announces Expanded Global Tab-cel Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results (Business Wire)
Oct-06-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:19AM	Loading…
Sep-21-23 09:19AM	Atara (ATRA) Up 11% on Regulatory Update From Blood Cancer Study (Zacks)
Sep-19-23 04:01PM	Atara Biotherapeutics Announces Plans to Submit Tab-cel® BLA in Q2 2024 Following FDA Agreement on Comparability (Business Wire)
Sep-01-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.16%
Aug-31-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapies in Autoimmune Panel Discussion at the Citi 18th Annual BioPharma Conference (Business Wire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Aug-08-23 05:30PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:18PM	Atara Biotherapeutics: Q2 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress (Business Wire)
Aug-04-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-01-23 04:01PM	Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023 (Business Wire)
Jul-31-23 04:01PM	Atara Biotherapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference (Business Wire) +7.28%
Jul-29-23 11:07AM	10 Stocks That Will Go Up 1000 Percent (Insider Monkey)
Jul-17-23 07:29AM	3 Doomed Biotech Stocks Destined for Disaster (InvestorPlace) +6.56%
Jul-07-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +11.45%
Jun-16-23 06:05AM	Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook (Simply Wall St.) -6.07%
04:01PM	Loading…
Jun-07-23 04:01PM	Atara Biotherapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (Business Wire)
Jun-05-23 09:00AM	Atara Biotherapeutics Presents Updated Tab-cel® Clinical Effectiveness Data at ASCO 2023 (Business Wire)
Jun-02-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-18-23 07:09AM	Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Are More Bearish Than They Used To Be (Simply Wall St.)
May-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:12PM	Atara Biotherapeutics: Q1 Earnings Snapshot (AP Finance)
04:01PM	Atara Biotherapeutics Announces First Quarter 2023 Financial Results and Operational Progress (Business Wire)
May-07-23 08:59AM	The Market Doesn't Like What It Sees From Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Revenues Yet (Simply Wall St.)
May-05-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.82%
May-01-23 04:01PM	Atara Biotherapeutics to Announce First Quarter 2023 Financial Results on Monday, May 8, 2023 (Business Wire)
Apr-16-23 12:08PM	3 Stocks to Buy That Could Be the Next Biotech Breakthrough (InvestorPlace)
Mar-31-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-24-23 09:35AM	Atara Biotherapeutics (ATRA) Loses -33.02% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Mar-03-23 04:01PM	Atara Biotherapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:40AM	Are Medical Stocks Lagging Apexigen, Inc. (APGN) This Year? (Zacks)
Mar-01-23 04:01PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 43rd Annual Health Care Conference (Business Wire)
Feb-21-23 04:01PM	Atara Biotherapeutics to Participate in the H.C. Wainwright Cell Therapy Virtual Conference (Business Wire) -9.96%
Feb-15-23 06:58AM	The past five years for Atara Biotherapeutics (NASDAQ:ATRA) investors has not been profitable (Simply Wall St.)
Feb-08-23 05:15PM	Atara Biotherapeutics (ATRA) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -7.69%
04:01PM	Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress (Business Wire)
06:00AM	Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO (tabelecleucel) (Business Wire)
Feb-06-23 08:00AM	Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on Wednesday, February 8, 2023 (Business Wire)
Feb-03-23 04:01PM	Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.31%
Jan-13-23 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-04-23 04:01PM	Atara Biotherapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-24-22 10:07AM	3 Under-the-Radar Biotech Stocks to Buy in 2022 (Motley Fool)
Dec-20-22 04:33PM	Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty (Business Wire)
Dec-19-22 08:00AM	Atara Biotherapeutics Announces Changes to Its Board of Directors (Business Wire)
07:00AM	Atara Biotherapeutics Ebvallo (tabelecleucel) Receives European Commission Approval as First Ever Therapy for Adults and Children with EBV+ PTLD (Business Wire)
Dec-15-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -10.82%
Dec-12-22 10:00AM	Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (ALLELE) of Tab-cel® at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire)
Dec-02-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +8.18%
Nov-23-22 08:00AM	Atara Biotherapeutics to Participate at the Evercore ISI 5th Annual HealthCONx Conference (Business Wire)
Nov-22-22 05:03AM	Newsflash: Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Analysts Have Been Trimming Their Revenue Forecasts (Simply Wall St.)
Nov-10-22 05:52AM	Atara Biotherapeutics Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS In Line (Simply Wall St.) +23.97%
Nov-09-22 04:01PM	Atara Biotherapeutics to Participate at the Stifel Healthcare Conference (Business Wire) -20.82%
Nov-08-22 05:15PM	Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Atara Biotherapeutics Announces Third Quarter 2022 Financial Results and Operational Progress (Business Wire)
Nov-04-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-01-22 04:05PM	Atara Biotherapeutics to Announce Third Quarter 2022 Financial Results on Tuesday, November 8, 2022 (Business Wire)
Oct-26-22 02:01AM	Atara Biotherapeutics Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022 (Business Wire)
Oct-14-22 07:08AM	CHMP Recommends Approval of Atara Biotherapeutics Ebvallo (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (Business Wire) -6.52%
Oct-13-22 12:51PM	BioMarin (BMRN) Hemophilia Gene Therapy BLA Gets FDA Acceptance (Zacks)
Oct-10-22 04:01PM	Atara Biotherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-07-22 10:01AM	Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T Therapy (Zacks) -8.61%
Oct-06-22 01:36PM	Acadia (ACAD) Rises More Than 14% in 3 Months: Here's Why (Zacks)
Sep-30-22 08:59AM	Horizon (HZNP) Completes Enrollment in Phase IV TED Study (Zacks)
Sep-29-22 11:09AM	Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis (Zacks) -5.47%
07:30AM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact (Benzinga)
Sep-28-22 04:01PM	Atara Biotherapeutics to Receive Additional Near-Term Milestone Payment Under Updated Tabelecleucel (Tab-cel®) Commercialization Agreement with Pierre Fabre (Business Wire) +15.32%
01:47PM	Merck's (MRK) Keytruda Gets Four New Approvals in Japan (Zacks)
Sep-27-22 10:13AM	Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral (Zacks)
Sep-21-22 06:32PM	Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod (Zacks) -5.53%
Sep-13-22 03:45PM	Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal (Zacks) -6.92%
08:44AM	Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review (Zacks)
Sep-07-22 01:31PM	IVERIC bio (ISEE) Posts Positive Top-Line Data From GA Study (Zacks) +7.57%
01:15PM	Gilead's (GILD) Tecartus Gets EC Nod for New Cancer Indication (Zacks)
Sep-06-22 09:26AM	Immunovant (IMVT) Up More Than 20% in Past 3 Months: Here's Why (Zacks)
Sep-05-22 10:21AM	Immuneering (IMRX) Files IND for Cancer Candidate IMM-1-104 (Zacks)
Aug-31-22 04:01PM	Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Citigroup 17th Annual Biopharma Conference (Business Wire)
12:12PM	Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study (Zacks)
Aug-25-22 11:52AM	Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down (Zacks)
Aug-24-22 06:03PM	Layoffs continue as biotech companies look to rein in downturn-era costs (American City Business Journals) +8.75%
Aug-23-22 01:53PM	Horizon (HZNP) Marketed Drugs Aid Growth, Stiff Rivalry a Woe (Zacks)
Aug-16-22 10:09AM	Horizon (HZNP) Inks Collaboration Deal with Q32 Bio for ADX-914 (Zacks) -7.49%
Aug-15-22 09:55AM	Does Atara Biotherapeutics (ATRA) Have the Potential to Rally 204% as Wall Street Analysts Expect? (Zacks) -8.56%
Aug-11-22 01:13PM	Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe (Zacks) -6.06%
Aug-09-22 03:01PM	Atara Lays Off 20% Of Its Workforce, Issues Update On Cell Therapies (Benzinga) +29.20%
Aug-08-22 05:35PM	Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +5.52%
04:01PM	Atara Biotherapeutics Announces Second Quarter 2022 Financial Results and Corporate Strategy Update (Business Wire)

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Touchon Pascal	President and CEO	Nov 16	Sale	0.39	20,409	7,939	655,496	Nov 20 05:31 PM
Joshi Manher	EVP, Chief Medical Officer	Nov 16	Sale	0.39	12,287	4,780	171,284	Nov 20 05:30 PM
Hyllengren Eric J	SVP, CFO	Nov 16	Sale	0.39	11,958	4,652	205,998	Nov 20 05:29 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Nov 16	Sale	0.39	8,856	3,445	277,143	Nov 20 05:31 PM
Murugan Amar	EVP, Chief Legal Officer	Nov 16	Sale	0.39	8,307	3,231	257,084	Nov 20 05:30 PM
Henrich Jill	EVP, Global Head RA & Quality	Nov 16	Sale	0.39	3,267	1,271	104,424	Nov 20 05:29 PM
Gallagher Carol Giltner	Director	Nov 14	Buy	0.31	90,980	28,186	459,418	Nov 15 05:07 PM
Gallagher Carol Giltner	Director	Nov 13	Buy	0.22	179,020	40,029	368,438	Nov 15 05:07 PM
DOBMEIER ERIC	Director	Nov 10	Buy	0.23	446,825	101,340	563,325	Nov 14 06:27 PM
HEIDEN WILLIAM K	Director	Nov 10	Buy	0.25	100,000	25,330	209,000	Nov 14 06:29 PM
Touchon Pascal	President and CEO	Aug 16	Sale	1.65	30,766	50,835	675,905	Aug 18 06:25 PM
Nguyen AnhCo	EVP, Chief Sci. & Tech Officer	Aug 16	Sale	1.65	15,126	24,997	285,999	Aug 18 06:25 PM
Murugan Amar	EVP, Chief Legal Officer	Aug 16	Sale	1.65	8,672	14,330	265,391	Aug 18 06:25 PM
Hyllengren Eric J	SVP, CFO	Aug 16	Sale	1.65	8,186	13,527	217,956	Aug 18 06:25 PM
Joshi Manher	EVP, Chief Medical Officer	Aug 16	Sale	1.65	6,975	11,526	183,571	Aug 18 06:25 PM
Henrich Jill	EVP, Global Head RA & Quality	Aug 16	Sale	1.65	3,346	5,531	107,691	Aug 18 06:25 PM
Touchon Pascal	President and CEO	Jun 27	Sale	1.66	14,291	23,723	706,671	Jun 29 04:15 PM
Touchon Pascal	President and CEO	May 16	Sale	2.04	29,766	60,633	720,962	May 18 08:17 PM
Banard Charlene A.	EVP, Chief Technical Officer	May 16	Sale	2.04	19,040	38,784	276,010	May 18 08:17 PM
Murugan Amar	EVP, Chief Legal Officer	May 16	Sale	2.04	8,389	17,089	270,945	May 18 08:17 PM
Hyllengren Eric J	SVP, CFO	May 16	Sale	2.04	7,918	16,131	226,142	May 18 08:17 PM
Touchon Pascal	President and CEO	Mar 02	Sale	3.63	15,679	56,868	750,728	Mar 06 06:49 PM
Koppikar Utpal	Chief Financial Officer	Mar 02	Sale	3.63	6,871	24,921	181,978	Mar 06 06:47 PM
Dupont Jakob	EVP, Head of R&D	Mar 02	Sale	3.63	5,074	18,403	290,794	Mar 06 06:46 PM
Murugan Amar	SVP, GC & Secretary	Mar 02	Sale	3.63	4,221	15,310	279,334	Mar 06 06:48 PM
Koppikar Utpal	Chief Financial Officer	Feb 07	Sale	5.46	2,485	13,568	188,849	Feb 09 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATRA

Atara Biotherapeutics Inc

Upgrade your FINVIZ experience